Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.

Cancer letters - 10 Apr 2023

Morimoto Yoshihiro, Yamashita Nami, Hirose Haruka, Fushimi Atsushi, Haratake Naoki, Daimon Tatsuaki, Bhattacharya Atrayee, Ahmad Rehan, Suzuki Yozo, Takahashi Hidekazu, Kufe Donald W

Abstract excerpt

Colorectal cancers (CRCs) harboring the BRAF(V600E) mutation are associated with aggressive disease and resistance to BRAF inhibitors by feedback activation of the receptor tyrosine kinase (RTK)→RAS→MAPK pathway. The oncogenic MUC1-C protein promotes progression of colitis to CRC; whereas there is no known involvement of MUC1-C in BRAF(V600E) CRCs. The present work demonstrates that MUC1 expression is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mucin-1

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Receptor Protein-Tyrosine Kinases

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 36878307
DOI: 10.1016/j.canlet.2023.216116
PMCID: PMC10408991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.PMID 36878307Read ↗

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

The molecular background of mucinous carcinoma beyond MUC2Semantic proximity Read ↗

Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistanceSemantic proximity Read ↗

Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer.Semantic proximity Read ↗

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in <i> BRAF <sup>V600E</sup> </i> colorectal cancerSemantic proximity Read ↗

Interaction between MUC1 and β-catenin promotes transformation of adenomas to adenocarcinomas in Familial Adenomatous PolyposisSemantic proximity Read ↗

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Semantic proximity Read ↗

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitorsSemantic proximity Read ↗

MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.Semantic proximity Read ↗

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancerSemantic proximity Read ↗

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.Semantic proximity Read ↗

MUC1-C drives MYC in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.